(0.25%) 5 144.25 points
(0.14%) 38 496 points
(0.39%) 17 915 points
(-0.30%) $83.60
(0.21%) $1.927
(0.05%) $2 348.30
(0.40%) $27.65
(2.48%) $944.95
(-0.20%) $0.933
(-0.30%) $10.99
(-0.36%) $0.798
(1.31%) $93.08
-6.26% HKD 20.20
Live Chart Being Loaded With Signals
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China...
Stats | |
---|---|
Tagesvolumen | 18.07M |
Durchschnittsvolumen | 5.10M |
Marktkapitalisierung | 63.00B |
EPS | HKD0 ( 2024-04-25 ) |
Last Dividend | HKD0.901 ( 2023-06-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.45 |
ATR14 | HKD0.0460 (0.23%) |
Volumen Korrelation
SINOPHARM GROUP CO LTD Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
SINOPHARM GROUP CO LTD Korrelation - Währung/Rohstoff
SINOPHARM GROUP CO LTD Finanzdaten
Annual | 2023 |
Umsatz: | HKD596.57B |
Bruttogewinn: | HKD48.51B (8.13 %) |
EPS: | HKD2.90 |
FY | 2023 |
Umsatz: | HKD596.57B |
Bruttogewinn: | HKD48.51B (8.13 %) |
EPS: | HKD2.90 |
FY | 2022 |
Umsatz: | HKD552.15B |
Bruttogewinn: | HKD47.43B (8.59 %) |
EPS: | HKD4.60 |
FY | 2021 |
Umsatz: | HKD521.05B |
Bruttogewinn: | HKD44.05B (8.45 %) |
EPS: | HKD2.49 |
Financial Reports:
No articles found.
SINOPHARM GROUP CO LTD Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.901 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0101 | 2010-04-29 |
Last Dividend | HKD0.901 | 2023-06-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | HKD6.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.6 | -- |
Div. Sustainability Score | 9.69 | |
Div.Growth Potential Score | 3.37 | |
Div. Directional Score | 6.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3326.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1553.HK | Ex Dividend Junior | 2023-06-09 | Annually | 0 | 0.00% | |
0595.HK | Ex Dividend Junior | 2023-09-06 | Annually | 0 | 0.00% | |
9616.HK | Ex Dividend Junior | 2023-08-07 | Annually | 0 | 0.00% | |
2119.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
1120.HK | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
0207.HK | Ex Dividend Junior | 2023-06-12 | Sporadic | 0 | 0.00% | |
3818.HK | Ex Dividend Knight | 2023-08-21 | Annually | 0 | 0.00% | |
1709.HK | No Dividend Player | 2023-09-13 | Annually | 0 | 0.00% | |
0737.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0155 | 1.500 | 9.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0358 | 1.200 | 8.81 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.194 | 1.500 | 8.96 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.395 | 0.800 | 8.03 | 6.42 | [1 - 3] |
quickRatioTTM | 1.034 | 0.800 | 8.63 | 6.90 | [0.8 - 2.5] |
cashRatioTTM | 0.264 | 1.500 | 9.64 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.188 | -1.500 | 6.87 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.69 | 1.000 | 3.45 | 3.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.49 | 2.00 | 2.17 | 4.34 | [0 - 30] |
freeCashFlowPerShareTTM | 22.23 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.965 | -1.500 | 6.14 | -9.21 | [0 - 2.5] |
grossProfitMarginTTM | 0.0838 | 1.000 | -1.937 | -1.937 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0381 | 1.000 | -1.238 | -1.238 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.017 | 1.000 | 5.46 | 5.46 | [0.2 - 2] |
assetTurnoverTTM | 2.31 | 0.800 | 10.00 | 8.00 | [0.5 - 2] |
Total Score | 9.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.31 | 1.000 | 9.67 | 0 | [1 - 100] |
returnOnEquityTTM | 0.194 | 2.50 | 9.33 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 22.23 | 2.00 | 2.59 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.75 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.49 | 2.00 | 2.17 | 4.34 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0825 | 1.000 | -0.437 | 0 | [0.1 - 0.5] |
Total Score | 3.37 |
SINOPHARM GROUP CO LTD
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.